Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000798 | 1.00 | FOLH1 (0.44) | FOLH1DPP4 | |
| SCHEMBL19590904 | 0.90 | DPP4 (0.43) | FOLH1DPP4 | |
| SCHEMBL23504903 | 0.90 | FOLH1 (0.43) | FOLH1DPP4 | |
| SCHEMBL9032439 | 0.89 | FOLH1 (0.45) | FOLH1DPP4 | |
| SCHEMBL18840376 | 0.88 | FOLH1 (0.45) | FOLH1DPP4 | |
| SCHEMBL16645333 | 0.88 | L3MBTL1 (0.45) | FOLH1DPP4 | |
| SCHEMBL1079200 | 0.88 | FOLH1 (0.45) | FOLH1DPP4 | |
| SCHEMBL19447720 | 0.88 | L3MBTL1 (0.45) | FOLH1DPP4 | |
| SCHEMBL16645337 | 0.88 | L3MBTL1 (0.45) | FOLH1DPP4 | |
| SCHEMBL1996255 | 0.88 | FOLH1 (0.45) | FOLH1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-4634174-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | claimed |
| EP-4622966-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-07-03 | — | — | US | claimed |
| WO-2024206577-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-10-03 | — | — | WO | claimed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | claimed |
| US-20230405157-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2023-12-21 | — | — | US | claimed |
| WO-2023219952-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| WO-2022261221-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-12-15 | — | — | WO | claimed |
| US-10988534-B2 | Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-04-27 | — | — | US | claimed |
| US-20200140543-A1 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-07 | — | — | US | claimed |
| EP-3256164-A2 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2017-12-20 | — | — | EP | claimed |
| WO-2016130539-A2 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2016-08-18 | — | — | WO | claimed |
| US-6713042-B2 | BUFFERING REAGENTS, CHELATING AGENTS AND STABILIZERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | claimed |
| US-20020122769-A1 | Ascorbic acid analogs for metalloradiopharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-09-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405157-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | MC3R, MC1R, MC4R | FOLH1 212/4885DPP4 3222/4885 |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | FOLH1 116/4885DPP4 2647/4885 |
| US-20020122769-A1 | Ascorbic acid analogs for metalloradiopharmaceuticals | SLC40A1, TTPA, SLC39A14 | FOLH1 45/4885DPP4 3846/4885 |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | FOLH1 335/4885DPP4 1569/4885 |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | KISS1R, GNRHR, PROKR1 | FOLH1 51/4885DPP4 525/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | FOLH1 121/4885DPP4 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.